Ann Meador
General Practice · Little Rock, ARNPI 1659331072
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Gilead at 34.0% of the total. Reporting peaked in 2024 at $637 and has fallen 77.1% since, to $146 in 2025. Among general practice clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$789
- Viiv Healthcare Company$359
- Indivior Inc.$313
- Alkermes, Inc.$275
- Theratechnologies Inc.$122
- Braeburn Inc.$81
- plus $385 from 13 others
What the payments were for
- Food & beverage$2,30899%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 27 | $789 |
| Viiv Healthcare Company | 20 | $359 |
| Indivior Inc. | 9 | $313 |
| Alkermes, Inc. | 10 | $275 |
| Theratechnologies Inc. | 7 | $122 |
| Braeburn Inc. | 4 | $81 |
| Merck | 4 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $55 |
| Johnson & Johnson | 3 | $51 |
| Neurocrine Biosciences, Inc. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Nevro Corp. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Pfizer | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$103
How this compares
$2,324 in reported general payments places this provider in the 90th percentile of 720 general practice providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 90 | $352,127 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 43 | $7,728 |
| Buprenorphine Hcl | 26 | $1,406 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $510 |
| Hydroxyzine Hcl | 22 | $380 |
| Atorvastatin Calcium | 26 | $236 |
| ProgesteroneProgesterone, Micronized | 11 | $222 |
| Omeprazole | 22 | $211 |
| Metoprolol Succinate | 11 | $136 |
| Fluoxetine Hcl | 13 | $109 |
| Losartan Potassium | 11 | $108 |
| Lisinopril | 21 | $95 |
| Amlodipine Besylate | 28 | $79 |
| Diazepam | 17 | $74 |
| Metformin Hcl | 14 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $789 | $352,12790 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 720 general practice providers in Arkansas.
Other general practice in Little Rock
- Samuel StrongLittle Rock$27K
- Thomas JeffersonLittle Rock$13K
- Tina NicholsLittle Rock$8K
- Samaria MascagniLittle Rock$7K
- David ReynoldsLittle Rock$3K
- Ashley McMillanLittle Rock$3K
- Ethan AkeLittle Rock$3K
- Roy HinsonLittle Rock$2K
- Stephen BannermanLittle Rock$2K
- Ned AlleyLittle Rock$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.